← back to search

Andrew S. Moore

Children’s Health Queensland Hospital and Health Service · AU
Area of research
Public Health, Environmental and Occupational Health · Hematology
Research interest
Research interests include Acute Lymphoblastic Leukemia research, Acute Myeloid Leukemia Research, Glioma Diagnosis and Treatment, and Childhood Cancer Survivors' Quality of Life.
h-index
40
citations
11,719
works
301
NIH funding
primary concept
Medicine
email

Recent publications

Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.
2026cited by 0position: contributordoi
Integrated Germline and Somatic Molecular Profiling to Detect Cancer Predisposition Has a High Clinical Impact in Poor-Prognosis Pediatric Cancer.
2026cited by 0position: contributordoi
Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain
Blood Neoplasia 2025cited by 4position: contributordoi
High Expression of NTRK1 in ETV6::RUNX1 Positive Acute Lymphoblastic Leukaemia Drives Factor Independence and Sensitivity to Larotrectinib.
2025cited by 0position: contributordoi
The 5’ fusion partner modulates response to the STAMP inhibitor asciminib in <i>ABL</i> -rearranged ALL
2025cited by 0position: contributordoi
Motion of VAPB molecules reveals ER–mitochondria contact site subdomains
Nature 2024cited by 114position: middledoi
Precision-guided treatment in high-risk pediatric cancers.
2024cited by 49position: contributordoi
Periodic ER-plasma membrane junctions support long-range Ca2+ signal integration in dendrites
Cell 2024cited by 46position: middledoi
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Nature Communications 2024cited by 17position: contributordoi
Structural dynamics of human ribosomes in situ reconstructed by exhaustive high-resolution template matching
Molecular Cell 2024cited by 15position: middledoi
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies <i>LMO2/STAG2</i> Rearrangements as Extremely High Risk
Cancer Discovery 2024cited by 13position: middledoi
Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies LMO2/STAG2 Rearrangements as Extremely High Risk.
2024cited by 13position: contributordoi
An interphase actin wave promotes mitochondrial content mixing and organelle homeostasis
Nature Communications 2024cited by 10position: middledoi
PARC: a phase I/II study evaluating the safety and activity of pegylated recombinant human arginase BCT-100 in relapsed/refractory cancers of children and young adults.
2024cited by 9position: contributordoi
Pearling Drives Mitochondrial DNA Nucleoid Distribution
2024cited by 4position: contributordoi
Characterization of Human Engraftment and Hemophagocytic Lymphohistiocytosis in NSG-SGM3 Neonate Mice Engrafted with Purified CD34<sup>+</sup> Hematopoietic Stem Cells.
2024cited by 3position: contributordoi
Mitochondrially-associated actin waves maintain organelle homeostasis and equitable inheritance
Current Opinion in Cell Biology 2024cited by 2position: middledoi
Providing Australian children and adolescents with equitable access to new and emerging therapies through clinical trials: a call to action.
2024cited by 2position: contributordoi
Incidence and survival for childhood cancer by endorsed non-stage prognostic indicators in Australia.
2024cited by 2position: contributordoi
Preventing adverse events during paediatric cancer treatment: protocol for a multi-site hybrid randomised controlled trial of catheter lock solutions (the CLOCK trial).
2024cited by 2position: contributordoi
Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress
Nature Cancer 2024cited by 1position: middledoi
Population-level 5-year event-free survival for children with cancer in Australia.
2024cited by 1position: contributordoi
Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosis.
2024cited by 0position: contributordoi
Supplementary Table S2 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi
Supplementary Table S22 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi
Supplementary Figure S1 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi
Supplementary Figure S3 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi
Supplementary Figure S4 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi
Supplementary Table S14 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi
Supplementary Table S10 from Biologic and Clinical Analysis of Childhood Gamma Delta T-ALL Identifies &lt;i&gt;LMO2/STAG2&lt;/i&gt; Rearrangements as Extremely High Risk
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 16 papers (2019–2025)Nicholas G. Gottardo · Hudson Institute of Medical Research5 papers (2019–2024) · 5 papers (2019–2025)Jennifer Lippincott‐Schwartz · Northwestern University5 papers (2021–2024)Susan L. Heatley · Centre for Cancer Biology4 papers (2022–2025)Danny R. Youlden · Griffith University4 papers (2019–2024)Deborah L. White · Stepping Hill Hospital4 papers (2022–2025)Joanne F. Aitken · Queensland University of Technology3 papers (2019–2020)Christopher C. Blyth · The Kids Research Institute Australia3 papers (2019–2021)Erika L.F. Holzbaur · Research Network (United States)3 papers (2021–2024)JD Pole · Queensland Health3 papers (2022–2024)Laura N Eadie · Royal Adelaide Hospital3 papers (2023–2025)Stephen Coscia · National Institute of Neurological Disorders and Stroke3 papers (2021–2024)Richard J. D’Andrea · South Australia Pathology2 papers (2021–2023)Harald F. Hess · Integral Consulting (United States)2 papers (2024–2024)Sumit Gupta · North Carolina Agricultural and Technical State University2 papers (2019–2024)Dirk Reinhardt · Charité - Universitätsmedizin Berlin2 papers (2020–2020)A. Lindsay Frazier · Harvard University2 papers (2019–2024)Christopher J. Obara · National Institute of Allergy and Infectious Diseases2 papers (2021–2024)Jacqueline Rehn · The University of Adelaide2 papers (2023–2025)